2024
FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study)
Ling R, Ueno R, Alamgeer M, Sundararajan K, Sundar R, Bailey M, Pilcher D, Subramaniam A. FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study). British Journal Of Anaesthesia 2024, 132: 695-706. PMID: 38378383, DOI: 10.1016/j.bja.2024.01.020.Peer-Reviewed Original ResearchConceptsElective surgeryCohort studyMulticentre retrospective cohort studyRetrospective multicentre cohort studyPatients admitted to intensive care unitsAssociated with poor outcomesAssociated with similar effectsAssociated with lower survivalCancer-related surgeryMulticentre cohort studyRetrospective cohort studyLong-term outcomesIntensive care unitAssociated with mortalityPoor outcomeFollow-upICU admissionPrimary outcomeCare unitSurgeryPatientsSurvival informationCancerFrailtyICU
2022
A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy
Leen A, Yap D, Teo C, Tan B, Molassiotis A, Ishiguro H, Fan S, Sundar R, Soon Y, Bandla A. A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy. Frontiers In Oncology 2022, 11: 763229. PMID: 35070969, PMCID: PMC8766304, DOI: 10.3389/fonc.2021.763229.Peer-Reviewed Original ResearchPaclitaxel-induced peripheral neuropathyPeripheral neuropathyTreatment arm compared to controlsMeta-analysisPooled resultsNeuroprotective interventionsSide effects of paclitaxelEffects of paclitaxelDisabling side effectsEffect of neuroprotectionNon-pharmacological interventionsNon-pharmacological trialsRelevant controlled trialsNon-pharmacological approachesRandom-effects modelEffective prevention strategiesBiomedical Literature DatabasePrimary outcomePharmacological trialsModerate heterogeneityPrevention strategiesPharmacological interventionsSystematic reviewLiterature databasesIntervention
2021
Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial
Tan B, Teo C, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Frontiers In Digital Health 2021, 3: 635524. PMID: 34713106, PMCID: PMC8521832, DOI: 10.3389/fdgth.2021.635524.Peer-Reviewed Original ResearchTumor marker levelsRandomised controlled trialsDrug dosePersonalised dosingSolid tumorsMarker levelsNational Healthcare GroupSignificant dose changesCapecitabine-based chemotherapyMetastatic solid tumorsDose of drugOpen-labelChemotherapy doseDose changesDosing recommendationsCohort expansionSingle-armSuboptimal efficacyProportion of participantsPrimary outcomeSecondary outcomesInterim analysisPhysician adherenceControlled trialsPrecision oncology